Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Boston University School of Medicine and the Massachusetts Board of Registration in Medicine. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Boston University School of Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity was planned in collaboration with the Massachusetts Department of Public Health, the Massachusetts Hospital Association, and the Massachusetts Medical Society.
This program meets the criteria of the Massachusetts Board of Registration in Medicine for 1 hour of risk management study.
This program meets the criteria of the Massachusetts Board of Registration in Medicine for 1 hour of opioid education.
In order to receive credit, participants must view the content of each module and complete the post-test and evaluation for each. Participants who receive a grade of 70% or greater on the post-tests will receive credit. Modules can be completed individually (each module is designated for 1 AMA PRA Category 1 Credit™).
[ View Full Accreditation Information ].
Educational Objectives
At the conclusion of this activity, participants will be able to:
- Apply a practical framework for decision-making on the initiation, maintenance, and discontinuation of opioid analgesics for the treatment of chronic pain.
Faculty
Daniel P. Alford, MD, MPH, FACP (Course Director)
Professor of Medicine
Boston University School of Medicine
Boston Medical Center
Faculty member has nothing to disclose with regards to commercial support. Faculty member indicates that he does not discuss unlabeled/investigational uses of a commercial product.
dan.alford@bmc.org
Jeffrey Baxter, MD
Assistant Professor
Department of Family Medicine and Community Health
University of Massachusetts Medical School
Faculty member has nothing to disclose with regards to commercial support. Faculty member indicates that he does not discuss unlabeled/investigational uses of a commercial product.
jeff.baxter@umassmed.edu
Sheila E. Chapman, MD
Assistant Professor of Medicine
Boston Medical Center
Boston University School of Medicine
Faculty member has nothing to disclose with regards to commercial support. Faculty member indicates that he does not discuss unlabeled/investigational uses of a commercial product.
sheila.chapman@bmc.org
Jane Liebschutz, MD, MPH, FACP
Associate Professor of Medicine and Social and Behavioral Sciences
Boston University Schools of Medicine and Public Health
Boston Medical Center
Faculty member has nothing to disclose with regards to commercial support. Faculty member indicates that she does not discuss unlabeled/investigational uses of a commercial product.
jane.liebschutz@bmc.org
John A. Renner, Jr., MD
Associate Professor of Psychiatry
Boston University School of Medicine
Associate Chief of Psychiatry, VA Boston Healthcare System
Faculty member holds stock in Johnson & Johnson. Faculty member indicates that he does discuss the off label use of buprenorphine/naloxone for pain, and parzosin for PTSD related nightmares.
john.renner@va.gov